DETROIT, MI- 24 April 2024 -In observance of Parkinson’s Disease Awareness Month, Quest Research Institute (Quest), a site within Alcanza Clinical Research’s network located in Detroit, emphasizes the importance of raising awareness about Parkinson’s disease (PD), recognizing its symptoms, and understanding the available clinical research avenues for patients.  With over two decades of experience and a broad spectrum of studies exploring investigational therapies and interventions, Quest is actively contributing to PD research. Kara Bardram, Quest’s Site Director, underscores Alcanza’s co ..read more

ORLANDO, FLA. – 22 de abril de 2024  ̶  Alcanza Clinical Research, una red de centros de investigación dirigida a ofrecer oportunidades a poblaciones desventajadas, anuncia la adquisición de FDI Clinical Research, una organización de investigación ubicada en San Juan, Puerto Rico fundada en 2002, y con un nuevo centro en la costa oeste, en la ciudad de Mayagüez. FDI, se especializa en ensayos clínicos de fase I a IV, abarcando enfermedades endocrinas y metabólicas, inmunología, hepatología, enfermedades infecciosas, oncología, afecciones respiratorias y reumatología. FDI dispone de u ..read more

Investigator Site Network Continues to Expand Network Size and Patient Reach with Acquisition of Multi-Specialty Clinical Research Center ORLANDO, FLA. – 9 April 2024 – Alcanza Clinical Research, a mission-focused investigator site network, has acquired Innovation Medical Research Center (Innovation), a multi-specialty clinical research center. This deal is a key part of Alcanza’s growth strategy, marking the ninth acquisition since 2021, and enabling the site network to expand its therapeutic area capabilities and diversity of study participants. Located in Palmetto Bay, Fla., Innovation cond ..read more

Alcanza Clinical Research Appoints James Clark, M.D., as Chief Medical Officer Newly Created Position Marks Pivotal Moment in Company’s Growth Journey CENTRAL FLORIDA – 12 March 2024 – Alcanza Clinical Research, a mission-focused investigator site network, has appointed James Clark, M.D., as its first-ever Chief Medical Officer, marking a milestone in Alcanza’s growth journey as it expands its network size and patient reach. In this role, Dr. Clark will be responsible for assembling and leading Alcanza’s Medical Advisory team – creating a new competitive advantage for the company that also ser ..read more

LAKE MARY, Fla., Feb. 19, 2024 /PRNewswire/ — hyperCORE International—a collaborative network of clinical trial sites (including Alcanza Clinical Research) spanning North America—is pleased to announce the appointment of two distinguished industry leaders to its executive team, effective immediately. Gwen Welty has joined in the role of Executive Director, tasked with leading hyperCORE’s operational endeavors. With extensive experience in the CRO and Site sectors, Ms. Welty’s addition strengthens hyperCORE’s position as it forges alliances with Sponsors and CROs. She welcomes en ..read more

Alcanza Clinical Research, a mission-focused investigator site network, announces the appointment of Bob Kinard as President and Chief Operating Officer. As a thirty-year healthcare veteran, Bob’s diverse experience includes operational and financial leadership, business development and strategic planning for a variety of health systems spanning physician practices, ambulatory and outpatient centers as well as specialty care. At Alcanza, Bob oversees clinical operations, patient engagement and quality and compliance functions. In addition, he will lead integration activities across the company ..read more

Boston, M.A, November 15, 2023  ̶   Ahead of Giving Tuesday, Alcanza Clinical Research is excited to announce its affiliation with Greater Gift, a non-profit organization dedicated to promoting awareness of the importance of clinical research and fostering a culture of gratitude and recognition within the clinical research community. Throughout the year, Alcanza has provided support to Greater Gift through financial donations and leadership. As a member of the Board of Directors, Carlos Orantes, Alcanza CEO, is actively involved in expanding awareness and industry involvement in ..read more

Dr. Rica Santiago Coastal Carolina Research Center  mRNA advances opened a world of new drug development pathways with the success of COVID vaccines. The first-ever vaccine for RSV shortly followed, and today there are many exciting new opportunities in the biopharmaceutical pipeline to treat and prevent disease. However, the initial excitement has recently turned into widespread frustration, due to a massive vaccine shortage in the updated COVID-19 vaccines and RSV shots for children.  Dr. Rica Santiago, Principal Investigator at Coastal Carolina Research Center discusses the pote ..read more

Farmington Hills, Mich., October 31, 2023   ̶   Quest Research Institute, part of the Alcanza Clinical Research site network, today announced the opening of a new research facility, increasing its capacity for Phase I-IV clinical trials and extending its ability to drive progress in innovative therapies for neurological and general medicines, vaccines and rare diseases. With 10,000 square feet, this state-of-the art facility expands on-site biomarker assessment and in-patient evaluation capabilities to support early phase studies across a range of therapeutic areas and late ..read more

Pediatric clinical research is on the rise, due in equal parts to recent draft FDA guidance that builds on previous guidance and clarifies expectations for pediatric clinical development, as well as increased public awareness and understanding of clinical research benefits in the post pandemic era. Generally speaking, pediatric medicine remains uncharted territory and is considered one of the most challenging areas of drug development, specifically for enrollment, procedure burden, as well as limitations with placebo use and age-appropriate formulations. Pediatric dosage formulation, the found ..read more